Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q3 2017 Earnings Presentation
10 slides from Anika Therapeutics's earnings presentation, Oct 26, 2017
Slide 1: Third Quarter 2017 Earnings Call Presentation
Third Quarter 2017 Earnings Call Presentation October 26, 2017 NASDAQ: ANIK 0
Slide 2: Safe Harbor Statement
Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s expanded commercial capabilities, product pipeline and associated timelines, upcoming corporate milestones, and growth strate
Slide 3: CINGAL: Second Phase III Clinical Trial Update
CINGAL: Second Phase III Clinical Trial Update First-in-class single-injection treatment combining FDA-approved HA and steroid for Pain Associated with Osteoarthritis (OA) Rapid and long-lasting pain relief through 6 months, with a strong safety profile First patient enrolled in Q2 2017; Compl
Slide 4: CINGAL: Commenced New 3-Month Extension Study
CINGAL: Commenced New 3-Month Extension Study CINGAL 13-01, a randomized, double-blind, placebo-controlled, active comparator Phase III study First Phase III study met all primary and secondary endpoints relative to saline in ITT analysis Second Phase III study patient enrollment completed Com
Slide 5: 510(k) Application for HA-based Bone Repair Treatment
510(k) Application for HA-based Bone Repair Treatment Submitted a 510(k) application in Q3 2017 Injectable HA-based bone repair treatment to fill bone voids Self-setting, osteoconductive bone graft substitute resorbable by the body and replaced by the growth of new bone during the healing proc
Slide 6: Global Commercial Expansion
Global Commercial Expansion MONOVISC Global Expansion CINGAL Growth Opportunity Worldwide revenue grew 50% Excellent real-world feedback year-over-year for the quarter on CINGAL: Dr. R. Timothy Ready for commercial launch of Deakon MONOVISC in India, Australia, Rapid adoption and commercial
Slide 7: HYALOFAST: The Future of Cartilage Repair
HYALOFAST: The Future of Cartilage Repair Innovative, Single-Step, and Cost Effective Solution Phase III Large Unmet Extensive Real- Clinical Trial Medical Need World Evidence Complete patient Potential global Over 11,000 patients enrollment in market opportunity of successfully treated 2018 over $5
Slide 8: The Next Wave of Growth for Anika Therapeutics
The Next Wave of Growth for Anika Therapeutics Continued R&D Strengthened Commercial Direct Investment & Operational Leadership Commercialization Positioned for Continued Growth and Value Creation 7
Slide 9: Q3 2017 Financial Highlights
Q3 2017 Financial Highlights Q3 2017 TOTAL REVENUE MONOVISC REVENUE INTERNATIONAL $27.2M 50% ORTHOBIOLOGICS $153M 10% Q3 2017 CASH & INVESTMENTS AS YEAR-OVER-YEAR OF SEPTEMBER 30, 2017; 5% GROWTH Q3 2016 OVER IN Q3 2017 REVENUE GROWTH NO DEBT 7% 77% $6.9M $0.46 Worldwide Product Net Income Diluted E
Slide 10: Q&A
Q&A Third Quarter 2017 Earnings Call Presentation October 26, 2017 NASDAQ: ANIK 9